This approach reveals the pharmacological activities of active ingredients in animal models, suggesting a fusion of traditional knowledge and modern methodologies.
The animal-based pharmacognosy has become a central science in the 21 st century, which represents a summarization of the conventional old knowledge of medicines and modern drug discovery. Using such models as rodents, zebrafish, and Caenorhabditis, the pharmacological activities of plant-derived active ingredients have been confirmed, indicating the use of active ingredients against inflammations, neuroprotective properties, antioxidant, antidiabetic characteristics, and wound-healing properties. High-end technological methodologies, such as assay of toxicity, behavioral analysis and disease-related models, have promoted both efficacy and safety analyses, whereas the current technological tools, such as LC-MS/MS, network pharmacology, and computational modeling, have increased accuracy, repeatability, and elucidation of the mechanism. Though interspecies variation, absence of standardization of extraction procedures and ethical issues remain a challenge in the field of animal-based pharmacognosy, it has been a revolutionary step in merging ethnomedicine and modern-day biomedical research. New paradigms, like high-throughput screening and omics methods, as well as alternative platforms, e.g., organ-on-chip systems are transforming the field, thereby providing more ethical, accurate, and translationally relevant practices. Combining or integrating the traditional wisdom and modern innovative approach, animal-based pharmacognosy can support sustainable drug discovery pipelines and offer immense opportunity in meeting the global health challenges.
No takes yet. Share an insight, caveat, or question.
Thakur et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: